LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Strona główna・Stock List・PROCEPT BioRobotics Corp

PROCEPT BioRobotics Corp

Closed

SectorHealthcare

28.69 9.3

Buy Sell

Overview

Share price change

24h

Current

Min

26.29

Max

28.73

Key metrics
By Trading Economics
Income	-1.8M -32M
Sales	6.7M 83M
EPS	-0.56
Profit margin	-38.058
Employees	888
EBITDA	-9.1M -31M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+38% upside

Dividends
By Dow Jones
Next Earnings	5 sie 2026

Market Stats
By TradingEconomics
Market Cap	135M 1.5B
Previous open	19.39
Previous close	28.69

News Sentiment

By Acuity

50%

150 / 346 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

52.655 / 56.31 Support & Resistance

PROCEPT BioRobotics Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 maj 2026, 22:50 UTC

Earnings

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 maj 2026, 22:49 UTC

Earnings

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 maj 2026, 22:32 UTC

Earnings

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 maj 2026, 23:48 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 maj 2026, 22:57 UTC

Market Talk

Earnings

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 maj 2026, 22:26 UTC

Earnings

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 maj 2026, 22:25 UTC

Earnings

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 maj 2026, 22:25 UTC

Earnings

Aristocrat Leisure Interim Dividend A$0.50/Security

12 maj 2026, 22:24 UTC

Earnings

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 maj 2026, 22:23 UTC

Earnings

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 maj 2026, 22:23 UTC

Earnings

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 maj 2026, 22:19 UTC

Earnings

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 maj 2026, 22:14 UTC

Earnings

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 maj 2026, 22:14 UTC

Earnings

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 maj 2026, 22:13 UTC

Earnings

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 maj 2026, 22:12 UTC

Earnings

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 maj 2026, 22:12 UTC

Earnings

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 maj 2026, 22:11 UTC

Earnings

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 maj 2026, 22:11 UTC

Earnings

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 maj 2026, 22:10 UTC

Earnings

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 maj 2026, 22:09 UTC

Earnings

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 maj 2026, 22:09 UTC

Earnings

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 maj 2026, 22:08 UTC

Earnings

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 maj 2026, 22:07 UTC

Earnings

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 maj 2026, 22:06 UTC

Earnings

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 maj 2026, 22:06 UTC

Earnings

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 maj 2026, 22:05 UTC

Earnings

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 maj 2026, 22:04 UTC

Earnings

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 maj 2026, 22:04 UTC

Earnings

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 maj 2026, 22:04 UTC

Earnings

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Peer Comparison

Price change

PROCEPT BioRobotics Corp Forecast

Price Target

By TipRanks

38% upside

12 Months Forecast

Average 36.5 USD 38%

High 60 USD

Low 20 USD

Based on 11 Wall Street analysts offering 12 month price targets forPROCEPT BioRobotics Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to PROCEPT BioRobotics Corp - Dist in the past 3 months.

Technical Score

By Trading Central

52.655 / 56.31Support & Resistance

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

150 / 346 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About PROCEPT BioRobotics Corp

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.